Bausch + Lomb Corp's latest earnings report shows steady growth despite a tough market.
On July 29, 2026, Bausch + Lomb Corp (BLCO.TO) announced its Q2 earnings, reporting earnings per share (EPS) of $0.16, which met expectations. The company also saw strong revenue growth across its segments.
Recent earnings trend
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.45B
52W high
$25.70
52W low
$18.76
1W change
+0.13%
Beta
0.55
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to rise 8.6% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.44
+8.6% Upside
Current Price
C$23.42
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
35.4%
Annualized
90-Day Vol
31.0%
Annualized
Trend (90d)
+35.9%
Annualized drift
90d Mean
C$26.63
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$24.44 | C$21.64 – C$27.61 |
| 60 trading days | C$25.51 | C$21.47 – C$30.31 |
| 90 trading days | C$26.63 | C$21.56 – C$32.89 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 11 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-10-28 | — | 0.2100 | — |
| 2026-06-30 | 2026-07-29 | 0.1600 | 0.1600 | +0.0% |
| 2026-03-31 | 2026-04-29 | 0.0800 | 0.0600 | +33.3% |
| 2025-12-31 | 2026-02-18 | 0.3200 | 0.3600 | -11.1% |
| 2025-09-30 | 2025-10-29 | 0.1800 | 0.1600 | +12.5% |
| 2025-06-30 | 2025-07-30 | 0.0700 | 0.0900 | -22.2% |
Advertisement
Investor takeaway: Although the EPS just met estimates, Bausch + Lomb is on a recovery path, managing competitive pressures while raising its revenue guidance for the year. Investors should consider the growth potential alongside the ongoing market challenges.
EPS Matches Estimates at $0.16
Bausch + Lomb's EPS of $0.16 matches estimates and marks a significant improvement from a loss of $0.18 a year ago, indicating a turnaround in financial performance.
Bull case
The company reported a year-over-year revenue increase of about 9%, showing signs of recovery, especially in its surgical and pharmaceutical segments. With an updated revenue guidance for the year, Bausch + Lomb is setting itself up for continued growth.
Bear case
Bausch + Lomb faces tough competition, particularly in the premium IOL and dry eye markets. Past recalls have affected customer trust, and ongoing operational issues could impact short-term performance.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
